title: Post-transplant lymphoproliferative disorders following solid-organ transplantation.
abstract: A post-transplant lymphoproliferative disorder (PTLD) is an uncommon but serious complication following solid-organ transplantation. The incidence varies, depending on the type of organ transplanted, the degree of immunosuppression, the number of episodes of acute rejection and a patient's immune status to Epstein-Barr virus. The incidence of PTLD is thought to be bimodal; cases in the first year after solid-organ transplantation are typically related to Epstein-Barr virus. A second incidence occurs more than 1 year following transplantation and is typically not related to Epstein-Barr virus. A variety of therapeutic approaches has been used for these patients, with more recent strategies including the use of rituximab, with or without combination chemotherapy. Efforts continue to be made to improve the outcome of patients with PTLD.
authors.affiliation: University of Minnesota, Department of Hematology/Oncology/Transplantation, 420 Delaware Street S.E., Minneapolis, MN 55455, USA. blaes004@umn.edu
authors.forename: Anne H
authors.initials: AH
authors.lastname: Blaes
authors.forename: Vicki A
authors.initials: VA
authors.lastname: Morrison
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D020031:Epstein-Barr Virus Infections / Q000150:complications; D006801:Humans; D007165:Immunosuppression Therapy; D008232:Lymphoproliferative Disorders / Q000175:diagnosis / Q000628:therapy* / Q000821:virology; D016377:Organ Transplantation; D012307:Risk Factors; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab